2020년 Business Management SL IA 입니다. (7점)View 한송's Full Store
본 문서는 2020년에 작성한 BM SL IA 이며 “How rational is Roche’s investment in R&D in personalized cancer treatments?”를 주제로 7점을 받았습니다. 도움이 되시길 바랍니다.
Roche is one of the world’s largest pharmaceutical companies that was established in 1896, in Switzerland. Roche was founded to serve innovative machines and diagnostic tests to patients throughout the world. It develops biologic medical products and delivers targeted therapies in oncology, neuroscience, infectious diseases, and so on. Roche has led cancer research and treatment for over 50 years including medicines for breast, skin, colon, ovarian, and others. Roche expanded its business by building a network of agents and subsidiaries in Europe and overseas mainly investing in New York. Currently, Roche has around 90,000 people working in more than a hundred countries with its annual investment around 9 billion Swiss francs that is to induce research and development (Roche). Successful investment in R&D would bring greater financial outcome than the amount that was invested. However, R&D heavily challenges the company because billions of dollars spent on the project would turn into failures, and failed projects would even threaten the values of the brand. Since this investment in R&D would bring great benefits to the company while also bringing risks, I pose the research question, “How rational is Roche’s investment in R&D in personalized cancer treatments?”
- 총 페이지수: 11 pages
- 과목명: Business Management
- 주제: How rational is Roche’s investment in R&D in personalized cancer treatments?
- The file is in PDF format.
2020년 Business Management SL IA 입니다. (7점)